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Carlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan,
Veronica Jude, Renee Madden, Charles F. LeMaistreSeizures as a complication of the infusion of autologous peripheral blood stem cells (PBSC) are rare. Seizures
during infusion of autologous PBSC in 3 of our patients prompted us to review our cell therapy and cytaphe-
resis protocols and procedures. We retrospectively analyzed 159 adult patients collected between January
2006 and July 2009. Patients were collected on either the COBE Spectra (Caridian BCT, Lakewood, CO) cell
separator (n5 85) or Fresenius AS (Fresenius Kabi AG, Bad Homburg, Germany) 104 cell separator (n5 74)
and mobilized with granulocyte-colony stimulating factor (G-CSF) alone (n 5 47), G-CSF and Plerixafor
(n 5 36), or G-CSF and chemotherapy (n 5 76). Patient characteristics (including age, weight, number of
collections, volume processed, disease type, and mobilization strategy) did not differ significantly between
the COBE and Fresenius cohorts, and adverse effects from infusion were similar except for 3 of 159 patients
who experienced seizures upon infusion of PBSC; all 3 were collected on the COBE and had PBSC product
white blood cell (WBC) counts of 590  103/mL or above. We prospectively correlated WBC counts mid-
collection, with final WBC counts to identify products with high WBC concentration during cytapheresis.
Fifty-one patients had 66 cytapheresis procedures using the COBE, with WBC counts midway and at the
end of collection of 287  103 6 150/mL and 273  103 6 144/mL, respectively. Mid-WBC therefore cor-
related withWBC at the end of the collection. Finally, we prospectively collected mid-WBC from 65 patients
who underwent 80 PBSC collections between June 2009 and January 2010 to identify products with midcol-
lection WBC concentration .450  103/mL. In those cases, additional autologous plasma was collected at
the time of collection to dilute the final product before cryopreservation. Patients who received diluted
products experienced no delays in engraftment and no additional seizure episodes occurred.
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Autologous hematopoietic stem cell transplantation
is a treatment strategy for restoring normal hematopoi-
etic function after myeloablative chemotherapy
in patients with hematologic malignancies [1-3]. The
procedure includes induction or reinduction
chemotherapy, mobilization and collection of CD341
cells through apheresis, administrationof high-dose che-
motherapy, and finally, infusion of the cells back into the
patient [4,5]. Cryopreservation of autologous stem cells
is performed after collection of peripheral blood stemTexas Transplant Institute, San Antonio, Texas.
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dimethyl sulfoxide (DMSO) with or without
hydroxyethyl starch are most commonly used to
protect cells from damage during the freezing process
[6-8]. Complications during infusion of thawed
autologous stem cells are mostly related to side effects
of DMSO and volume infused at the time of
transplantation [9-13]. These include nausea, vomiting,
hyper- and hypotension, cardiac arrhythmias, and
gastrointestinal side effects, among others. Rarely,
tonic-clonic seizures have been described after infusion
of cryopreserved PBSC [10,14]. The etiology of
seizures in these patients is poorly understood.
Tonic-clonic seizures after infusion of PBSC prod-
uct occurred in 3 patients between 2006 and 2009. We
performed a retrospective review of our cell therapy
and cytapheresis protocols and procedures to investi-
gate these adverse events. This retrospective analysis
identified high white blood cell (WBC) concentrations
in the PBSC product before freezing as a causative
factor associated with these adverse events. We1055
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with autologous plasma based on WBC count during
collection of PBSC. We then evaluated infusion-
related adverse events and engraftment in subsequent
patients including those that required dilution of
PBSC products because of high WBC concentration
before product freezing. Finally, the use of both Frese-
nius and COBE apheresis instruments for collection of
PBSC allowed us to compare product characteristics
using these 2 collection devices.Table 1. Patient Characteristics
Disease
Multiple myeloma 89
Non-Hodgkin lymphoma 42
Hodgkin’s disease 20
Testicular carcinoma 5
Neuroblastoma 1
Acute lymphocytic leukemia 1
Acute promyelocytic leukemia 1
Mobilization strategy
G-CSF alone 47
G-CSF + chemotherapy 76
G-CSF + plerixafor 36
Mobilization device
COBE spectra 85
Fresenius ASC04 74
Age at collection
56 ± 14METHODS
We retrospectively selected sequential patients who
underwent PBSC collection at theTexasTransplant In-
stitute between January 2006 and July 2009 in anticipa-
tion of autologous transplant. This was the time interval
when seizure-related adverse events were identified dur-
ing infusion of PBSC. Patients that developed seizures
duringPBSC infusionwere included in this analysis. Pa-
tients underwent mobilization with granulocyte-colony
stimulating factor (G-CSF), either with or without pler-
ixafor, or after G-CSF and chemotherapy. Patients
underwent apheresis with either a COBESpectra (Cari-
dian BCT, Lakewood, CO) or Fresenius AS104 (Frese-
nius Kabi AG, Bad Homburg, Germany) according to
standard procedures. Patients were randomly collected
on either device by our cytapheresis department accord-
ing tomachine availability.Apheresis productswere cry-
opreserved in 10% DMSO using controlled rate
freezing. PBSCwere then stored in liquid nitrogen until
the day of transplantation when they were thawed at the
bedside and infused. Patients received premedication 15
to 30minutes before PBSC infusion consisting ofmeth-
ylprednisolone 20mganddiphenhydramine 25mgboth
given orally. Data from patients who failed to mobilize
were not included in this analysis. Clinical data from 3
patients who developed seizures during infusion of
PBSC included imaging studies of the brain, electroen-
cephalogram, cerebral spinal fluid analysis, electrolyte
analysis, arterial blood gases, and evaluation of other
medications and past history to exclude conditions pre-
disposing to seizures (including prior history of seizures,
head trauma, and leptomeningeal carcinomatosis).
We identified high WBC concentration in PBSC
product after collection as the only laboratory pa-
rameter associated with seizures. We then evaluated
the possibility of predicting WBC concentration at
the end of the collection by measuring WBC in
the collection bag at the halfway volume of cytaphe-
resis. All patients underwent an 18- to 20-liter blood
volume collection and mid-WBC counts were ob-
tained at 9 to 10 liters into their PBSC collection.
This information allowed us to collect autologous
plasma during PBSC collection in patients with
high WBC concentration and dilute these products
before freezing.Finally, in a subsequent cohort, we prospectively
collected data from patients who underwent PBSC
collections in anticipation of an autologous or alloge-
neic stem cell transplant between June 2009 and Janu-
ary 2010.WBC counts were obtained halfway through
their PBSC collections. Products with WBC counts
.450  103/mL were identified, additional plasma
was collected, and PBSC was diluted before cryopres-
ervation. Infusion-related adverse events and engraft-
ment were then evaluated in these patients. All data
was statistically analyzed, and all P values were calcu-
lated using a 2-tailed, heteroscedastic Student t test;
statistical significance was defined as P\ .05.RESULTS
One hundred fifty-nine patients were selected for
the retrospective review of PBSC infusion-related ad-
verse events. Patients were mobilized with G-CSF
alone (n 5 47), G-CSF 1 plerixafor (n 5 36), or
G-CSF 1 chemotherapy (n 5 76). Patients were col-
lected using either the COBE Spectra (n 5 85) or
the Fresenius AS104 (n 5 74). Patients underwent
transplantation for multiple myeloma (n 5 89), non-
Hodgkin lymphoma (n 5 42), Hodgkin disease
(n 5 20), testicular cancer (n 5 5), neuroblastoma
(n 5 1), acute lymphocytic leukemia (n 5 1), or acute
promyelocytic leukemia (n 5 1) (Table 1).
Parameters measured during collection (Table 2)
included age, weight at collection, number of collec-
tions per patient, patient’s blood volume processed
during each collection, volume of product at the end
of the collection, and total time per collection. Volume
of product at the end of collectionwas larger in the Fre-
senius group than the COBE group (402 6 72.0 mL
versus 2416 56.8 mL, respectively, P\ .0001) and re-
quired a longer time of collection (5.20 6 0.88 hours
versus 4.256 0.64 hours, respectively, P\ .0001).
Differences in PBSC product are described in
Table 3. Patients collected on the COBE separator
Table 2. PBSC Collection
COBE (±SD) Fresenius (±SD)
Number of products 165 180
Number of patients 85 74
Age at collection 56 ± 14 56 ± 15
Weight at collection (kg) 82.7 ± 17.9 79.5 ± 15.9
Collections/patient 2 ± 1 2 ± 1
Blood volume processed at end of
collection (L)
18.0 ± 2.4 18.1 ± 2.7
*Product volume (mL) 241 ± 56.8 402 ± 72.0
*Collection time (hours) 4.25 ± 0.65 5.20 ± 0.88
*P < .05.
Table 4. CD34 Analysis
COBE (±SD) Fresenius (±SD)
Peripheral CD34+/mL 24.0 ± 43.8 25.3 ± 79.1
*Product CD34+/mL 726.7 ± 1325.9 264.63 ± 781.0
*Product/peripheral CD34+ 24.8 ± 10.9 10.9 ± 6.6
Absolute product CD34+ cells (108) 1.77 ± 3.52 1.14 ± 3.35
Product CD34+/kg (106) 2.02 ± 4.67 1.39 ± 4.15
Total CD34+ cells infused (106/kg) 3.85 ± 3.20 3.85 ± 2.24
*P < .05.
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lower cell viability than patients collected with the Fre-
senius. Patients collected on the COBE had a higher
number of total nucleated count but a lower percent-
age of mononuclear cells than patients collected on
the Fresenius.
Absolute CD341 cells in the PBSC product,
CD341 cells/kg, and total CD341 cells/kg infused
at transplantation were not significantly different
(Table 4). CD341 yields were calculated as the ratio
of CD341 cells/mL of the PBSC product to the pa-
tient’s peripheral blood CD341 cells/mL taken on
the day of collection and before start of cytapheresis.
CD341 cell yields (Figure 1A and B) were significantly
higher on the COBE than the Fresenius. CD341 cell
yields were higher across all disease types and mobili-
zation strategies (data not shown).
Seizures are included among the category of seri-
ous adverse events during infusion of PBSC at our cen-
ter. PBSC infusion-related serious adverse events
undergo internal review through our quality manage-
ment plan. No serious adverse events occurred during
PBSC infusion except that 3 of 159 patients experi-
enced tonic-clonic seizures during infusion of PBSC;
all 3 were collected on the COBE and all 3 had product
WBC of 590 103/mL or above (compared with a me-
dian of 163.3  103/mL for all other products)
(Figure 2). All 3 patients with infusion-related seizures
had multiple myeloma with small paraprotein levels
at the time of PBSC collection (Table 5). Evaluation
of patients developing seizures did not identifyTable 3. PBSC Product
COBE (±SD) Fresenius (±SD)
Peripheral WBC (103/mL) 36.6 ± 18.9 33.3 ± 24.5
*Product WBC(103/mL) 163.3 ± 136.0 55.8 ± 29.3
HCT (%) 3.1 ± 3.3 3.2 ± 1.7
*TNC (1010) 3.51 ± 1.86 1.95 ± 1.19
*MNC (1010) 2.36 ± 1.19 1.60 ± 0.094
*MNC (%) 75.0 ± 23.3 85.0 ± 10.8
Volume before freezing (mL) 100 ± 54 100 ± 32
*Postfreeze viability (%) 70 ± 14 75 ± 10
DMSO (mL) 10 ± 5.4 10 ± 3.2
TNC indicates total nucleated count; MNC, mononuclear cells.
*P < .05.abnormalities in imaging studies, cerebrospinal fluid
analysis, electrolytes, or past history, which might
explain the etiology of seizures. Electroencephalogram
performed within 24 hours of seizures only demon-
strated slow waves. Seizures lasted 5 to 10 minutes
and were not associated with significant changes in
blood pressure, desaturation, or documented cardiac
arrhythmias. All patients fully recovered after a postic-
tal state with no further neurologic sequel.
We then correlated WBC counts midway and at
the end of PBSC collections. Fourteen patients had
a total of 15 apheresis procedures using the Fresenius
cell separator. Mid- and post-WBC concentrations
were 646 23 103/mL and 696 20 103/mL, respec-
tively. Fifty-one patients had 66 cytapheresis proce-
dures using COBE, with WBC counts obtained
midway and at the end of collection of 287 6 150 
103/mL and 273 6 144  103/mL, respectively.Figure 1. (A) Fresenius peripheral CD34 versus product CD34. (B)
COBE peripheral CD34 versus product CD34.
Figure 2. COBE versus Fresenius product WBC concetration (103/
mL).
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of the collection in both the COBE and Fresenius co-
horts (r25 .940 and r25 .904, respectively) (Figure 3A
and B).
Using this information, we prospectively collected
mid-WBC in order to identify high WBC in 65 pa-
tients who underwent 80 hematopoietic stem cell
transplant collections in anticipation of an autologous
(n5 58) or allogeneic (n5 7) stem cell transplantation
between June 2009 and January 2010. Collections for
these patients were performed using the COBE Spec-
tra (n 5 65) or the Fresenius AS104 (n 5 15). WBC
concentrations were obtained halfway through their
collections. Products with mid-collection WBC con-
centration greater than 450  103/mL were identified,
and additional autologous plasma was collected at the
time of collection so that the final product could be di-
luted before cryopreservation. We collected enough
autologous plasma to dilute PBSC products to a con-
centration \450  103/mL. Patient weight, volume
of PBSC product, and number of CD34 cells/kg in-
fused during transplantation did not differ significantly
between the patients who received diluted PBSC prod-
uct and those who did not (Table 6). Importantly,
there was also no difference observed in days to en-
graftment between the 2 groups, in either ANC en-
graftment (12 6 1.3 days versus 11.5 6 1.3 days,
dilution versus nondilution, P5 .760) or in platelet en-
graftment (186 3.7 days versus 166 2.7 days, dilutionTable 5. Characteristics of Patients with PBSC Infusion Seizures
Age (years) Weight (kg) Diagnosis
Patient #1 60 80 Multiple myeloma
Patient #2 53 68 Multiple myeloma
Patient #3 45 63 Mutliple myelomaversus nondilution, P 5 .561). Similarly, the precryo-
preservation cell viability and product mononuclear
cells percentage did not differ significantly between
the 2 cohorts; the only significant difference was found
in postthaw viability, where the undiluted products
had a viability nearly 10% greater than the diluted
products (63 6 13% versus 54 6 13%, respectively,
P 5 .008). No serious adverse infusion effects were
observed in either group.DISCUSSION
Infusion of thawed PBSC can be associated with
side effects that are usually mild and reversible
[9-13]. These include nausea, vomiting, abdominal
cramping, diarrhea, shortness of breath, chest
pressure, changes in blood pressure, and cardiac
arrhythmias, among others. Some of these side
effects are thought to be related to DMSO used as
a cryopreservant, red cells in the product, volume of
product infused, and vagal responses. Epileptogenic
seizures associated with infusion of thawed PBSC are
rare and only described in case reports [10,14]. The
etiology of these seizures is therefore poorly
understood. In our retrospective review, an elevated
WBC concentration before PBSC freezing correlated
with seizures during PBSC infusion.
Several studies have described the effect of cell
concentration on viability and the side effects of in-
fused cryopreserved autologous PBSC [15-17].
Rowley et al. [18] established that median concentra-
tion 370 6 190  103 (range: 40-800) cells/mL were
not associated with loss of engraftment or unexpected
infusion-related toxicities. Infusion-related seizures in
our cohort occurred only in patients with high WBC
concentrations in PBSC products and were only seen
in patients collected on the COBE Spectra. Other clin-
ical factors associated with seizures were excluded. It is
unclear how a high WBC concentration could lead to
PBSC infusion-related seizures in our patients. In-
creased thickness and occasional clumping of PBSC
products with high WBC concentration were occa-
sionally seen at the time of thawing and before infu-
sion. It is therefore possible that clumping of the
PBSC product contributed to seizure episodes in our
patients.
We first identified PBSC products with highWBC
concentration by measuring WBC during apheresis.
Our data showed a strong correlation betweenM-Spike (g/dL) Mobilization Volume of PBSC Frozen (mL)
0.8 G-CSF 200
0.5 G-CSF 160
1.1 G-CSF 200
Figure 3. (A) Correlation ofWBC at collection midpoint withWBC in
PBSC product—Fresenius. (B) Correlation of WBC at collection mid-
point with WBC in PBSC product—COBE.
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accurately predict products with high WBC that can
potentially be associated with seizures. Identification
of PBSC collection with high WBC concentration
during apheresis allowed us to collect additional
autologous plasma to dilute these products before
cryopreservation. Identification of PBSC products
with high WBC concentration can obviate the
unnecessary dilution of all products and therefore
decrease the cost associated with cryopreservation
and storage of PBSC. We used WBC concentrationsTable 6. Dilution of PBSC with High WBC
Plasma Added
(Diluted) (N 5 29)
Plasma Not Added
(Undiluted) (N 5 51)
*WBC (103/mL) 525 ± 164 357 ± 93.2
Final WBC (103/mL) 351 ± 60.8 335 ± 65.1
*TNC (1010) 12.4 ± 3.8 7.35 ± 2.3
*Total volume frozen (mL) 400 ± 88.5 200 ± 51.2
Pre cryo viab. (%) 98 ± 6.1 98 ± 1.4
*Postthaw viab. (%) 54 ± 13.2 63 ± 12.7
% MNC 60 ± 21.9 65 ± 21.9
CD34/kg infused (106/kg) 3.85 ± 1.48 4.66 ± 1.68
ANC engraftment (days) 12.0 ± 1.3 11.5 ± 1.3
PLTengraftment (days) 18.0 ± 3.7 16.0 ± 2.7
MNC indicates mononuclear cells.
*P < .05..450  103/mL as the cutoff to use autologous plasma
for dilution of PBSC products. This concentration is
both within the average concentration used to cryopre-
serve PBSC as described by others [15-17] and a cell
concentration not associated with seizures in our
study. Subsequent evaluation of patients identified no
adverse effects after dilution with autologous plasma
in PBSC products with high WBC concentration.
Finally, we also added 10% of anticoagulant citrate
dextrose solution at the time of thawing in patients
requiring dilution of PBSC products because of high
WBC concentration. It is therefore possible that
absence of seizures in patients with diluted PBSC
products is also related to addition of Acid-citrate-
dextrose (ACD) before infusion.
Use of both Fresenius AS104 and COBE Spectra
cell separators gave us the opportunity to determinedif-
ferences in product characteristics collected with these
2 devices. Cytapheresis on the Fresenius AS104 cell
separator tookmore time and produced fewer total cells
and lower CD341 cell yields than the COBE Spectra.
Absolute CD341 cells per collection were not signifi-
cantly different because the total volume of the PBSC
product per collection was higher with the Fresenius
AS104.Only patients collectedwith theCOBESpectra
developed seizures during PBSC infusion. PBSC
products collected with the COBE spectra had higher
WBC and a lower percentage of mononuclear cells.
In conclusion, a higher number ofWBC including
mature granulocytes in COBE Spectra collections is
a possible cause of PBSC infusion-related seizures. Di-
lution of PBSC with high WBC concentration with
autologous plasma and addition of ACD during thaw-
ing prevented additional seizure episodes. Since mak-
ing these changes, we continue to monitor patients
for PBSC infusion-related seizures, other infusion-
related serious adverse events, and engraftment.ACKNOWLEDGMENTS
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